Common use of Forward Looking Statement Clause in Contracts

Forward Looking Statement. This press release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management's beliefs and assumptions, current expectations, estimates and projections. Statements that are not historical facts, including statements which are preceded by, followed by, or that include, the words "believes," "anticipates," "plans," "expects" or similar expressions and statements are forward-looking statements. Endo's estimated or anticipated future results, product performance or other non- historical facts are forward-looking and reflect Endo's current perspective on existing trends and information. Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict. These statements are subject to risks and uncertainties and, therefore, actual results may differ materially from those expressed or implied by these forward-looking statements. The reader should not rely on any forward-looking statement. The Company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. Several important factors, in addition to the specific factors discussed in connection with these forward-looking statements individually, could affect the future results of Endo and could cause those results to differ materially from those expressed in the forward-looking statements contained in this press release. Important factors that may affect future results include, but are not limited to: market acceptance of the Company's products and the impact of competitive products and pricing; dependence on sole source suppliers; the success of the Company's product development activities and the timeliness with which regulatory authorizations and product launches may be achieved; successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions; the availability on commercially reasonable terms of raw materials and other third party manufactured products; exposure to product liability and other lawsuits and contingencies; dependence on third party suppliers, distributors and collaboration partners; the ability to timely and cost effectively integrate acquisitions; uncertainty associated with pre-clinical studies and clinical trials and regulatory approval; uncertainty of market acceptance of new products; the difficulty of predicting FDA approvals; risks with respect to technology and product development; the effect of competing products and prices; uncertainties regarding intellectual property protection; uncertainties as to the outcome of litigation; changes in operating results; impact of competitive products and pricing; product development; changes in laws and regulations; customer demand; possible future litigation; availability of future financing and reimbursement policies of government and private health insurers and others; and other risks and uncertainties detailed in Endo's filings with the Securities and Exchange Commission, including its Registration Statement on Form S-3 filed with the SEC on April 30, 2004, as amended. Readers should evaluate any statement in light of these important factors.

Forward Looking Statement. This press release contains Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed or implied by such forward-looking statementsinformation, within including risks associated with investments in private and publicly listed companies such as Earths Energy Limited (Earths Energy or Company); risks associated with general economic conditions; the meaning of Section 27A risk that further funding may be required but unavailable for the ongoing development of the Securities Act Company’s projects or future acquisitions; changes in government regulations, policies or legislation (whether in Australia or elsewhere); unforeseen expenses; fluctuations in commodity prices; fluctuation in exchange rates; litigation risk; the inherent risks and dangers of 1933 development operations in general; risk of continued negative operating cashflow; the possibility that required permits may not be obtained; environmental risks; general risks associated with the feasibility and Section 21E development of the Securities Exchange Act Company’s projects; future actions by government whether in Australia or elsewhere and whether or not they could have reasonably be foreseen or not; breach of 1934any of the contracts through which the Company holds property rights; defects in or challenges to the Company’s property interests; uninsured hazards; disruptions to the Company’s supplies or service providers; reliance on key personnel, retention of key employees and the impact of the COVID-19 pandemic on the Company’s business and operations. Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management of the Company made in light of their experience and their perception of trends, current conditions and expected developments, as amended, well as other factors that are based on management's beliefs management believes to be relevant and assumptions, current expectations, estimates and projections. Statements reasonable in the circumstances at the date that are not historical facts, including statements which are preceded by, followed by, or that include, the words "believes," "anticipates," "plans," "expects" or similar expressions and such statements are made, but which may prove to be incorrect. The Company believes that the assumptions and expectations reflected in such forward-looking statementsinformation are reasonable. Endo's estimated or anticipated future resultsAssumptions have been made regarding, product performance or among other non- historical facts are forward-looking and reflect Endo's current perspective on existing trends and information. Many of things: the factors that will determine energy market, the Company's ’s peers, the Company’s ability to carry on its future results are beyond development works, construction and production activities, the timely receipt of required approvals, the price of electricity, the ability of the Company to control or predictoperate in a safe, efficient and effective manner and the ability of the Company to obtain financing as and when required and on reasonable terms. These statements Readers are subject cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Although the Company has attempted to risks and uncertainties and, therefore, identify important factors that could cause actual results may to differ materially from those expressed or implied by these contained in forward-looking statementsinformation, there may be other factors that cause the Company’s results not to be as anticipated, estimated or intended. The reader There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not rely place undue reliance on any forward-looking statementinformation. The Company undertakes no obligation does not undertake to update any forward-looking statements whether as a result of new information, future events or otherwise. Several important factors, except in addition to the specific factors discussed in connection accordance with these forward-looking statements individually, could affect the future results of Endo and could cause those results to differ materially from those expressed in the forward-looking statements contained in this press release. Important factors that may affect future results include, but are not limited to: market acceptance of the Company's products and the impact of competitive products and pricing; dependence on sole source suppliers; the success of the Company's product development activities and the timeliness with which regulatory authorizations and product launches may be achieved; successful compliance with extensive, costly, complex and evolving governmental regulations and restrictions; the availability on commercially reasonable terms of raw materials and other third party manufactured products; exposure to product liability and other lawsuits and contingencies; dependence on third party suppliers, distributors and collaboration partners; the ability to timely and cost effectively integrate acquisitions; uncertainty associated with pre-clinical studies and clinical trials and regulatory approval; uncertainty of market acceptance of new products; the difficulty of predicting FDA approvals; risks with respect to technology and product development; the effect of competing products and prices; uncertainties regarding intellectual property protection; uncertainties as to the outcome of litigation; changes in operating results; impact of competitive products and pricing; product development; changes in laws and regulations; customer demand; possible future litigation; availability of future financing and reimbursement policies of government and private health insurers and others; and other risks and uncertainties detailed in Endo's filings with the Securities and Exchange Commission, including its Registration Statement on Form S-3 filed with the SEC on April 30, 2004, as amended. Readers should evaluate any statement in light of these important factorsapplicable securities laws.